glp-1 agonists cardiovascular diseases The effects of receptor beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 Agonists For Obesity In
Description
With DPP4 inhibitor as a referent comparator, the estimates for different GLP1 receptor agonists numerically differed, but heterogeneity was not statistically significant ( p = 0.641)
Studies of the same species also varied, with a follow-up of patients treated with GLP-1RAs (74) showing no significant difference in calcitonin concentrations between liraglutide and placebo and no change in the risk of thyroid C-cell tumors
Journal of Public Health Management and Practice, 30(5)
Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis
Tardif JC, Kouz S, Waters David D, Bertrand OF et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction
